Comparison between three adjuvants for a vaccine against canine leishmaniasis: In vitro evaluation of macrophage killing ability

被引:5
作者
Trotta, T. [1 ]
Fasanella, A. [2 ]
Scaltrito, D. [2 ]
Gradoni, L. [3 ]
Mitolo, V. [4 ]
Brandonisio, O. [5 ]
Acquafredda, A. [4 ]
Panaro, M. A. [4 ]
机构
[1] Univ Foggia, Osped Riuniti, Dipartimento Sci Biomed, Sez Anat Umana, I-71100 Foggia, Italy
[2] Ist Zooprofilatt Sperimentale Puglia & Basilicata, I-71100 Foggia, Italy
[3] Ist Super Sanita, Dipartimento MIPI, I-00161 Rome, Italy
[4] Univ Bari, Istol Policlin, Dipartimento Anat Umana & Istol, I-70124 Bari, Italy
[5] Univ Bari, Dipartimento Clin Med Immunol & Malattie Infett, Sez Microbiol & Immunol, Istol Policlin, I-70124 Bari, Italy
关键词
Leishmania; Leishmaniosis; Adjuvant; Vaccine; Dog; VISCERAL LEISHMANIASIS; RECOMBINANT ANTIGENS; IMMUNE-RESPONSES; DOUBLE-BLIND; INFANTUM; DOGS; INFECTION; PROTECTION;
D O I
10.1016/j.cimid.2009.12.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The aim of this study was to evaluate, in terms of dog macrophage killing ability in vitro, a vaccine based on Leishmania infantum promastigote soluble antigen (LSA) formulated with three different adjuvants (BCG, AdjuPrime (TM), MPL/TDM/CWS). A significant increase of the macrophage killing ability was observed in dogs vaccinated with LSA + MPL/TDM/CWS after 1 month from vaccination. A similar increase of macrophage parasitocidal ability was present only after 5 months in dogs vaccinated with LSA + BCG or LSA + AdjuPrime (TM). In all dogs the augmented killing percentage was still present after 12 months from vaccination. Therefore, in particular LSA + MPL/TDM/CWS vaccine seems promising for further studies in dogs. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 33 条
[1]   Effects of β-glucans on the immune system [J].
Akramiene, Dalia ;
Kondrotas, Anatolijus ;
Didziapetriene, Janina ;
Kevelaitis, Egidijus .
MEDICINA-LITHUANIA, 2007, 43 (08) :597-606
[2]   Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity [J].
Bogdan, C ;
Röllinghoff, M ;
Diefenbach, A .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (01) :64-76
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]  
BRANDONISIO O, 1992, EUR J EPIDEMIOL, V8, P273, DOI 10.1007/BF00144813
[5]   Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients [J].
Cabrera, M ;
Blackwell, JM ;
Castes, M ;
Trujillo, D ;
Convit, J ;
Shaw, MA .
PARASITE IMMUNOLOGY, 2000, 22 (02) :73-79
[6]   Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant [J].
Chaitra, M. G. ;
Nayak, R. ;
Shaila, M. S. .
VACCINE, 2007, 25 (41) :7168-7176
[7]   Second-generation vaccines against leishmaniasis [J].
Coler, RN ;
Reed, SG .
TRENDS IN PARASITOLOGY, 2005, 21 (05) :244-249
[8]   Sabotage and exploitation in macrophages parasitized by intracellular protozoans [J].
Denkers, EY ;
Butcher, BA .
TRENDS IN PARASITOLOGY, 2005, 21 (01) :35-41
[9]  
Evans D. A., 1978, Methods of cultivating parasites in vitro., P55
[10]  
Evans Jay T, 2003, Expert Rev Vaccines, V2, P219, DOI 10.1586/14760584.2.2.219